Company Overview - VYNE Therapeutics is focused on developing therapies for inflammatory and immune-mediated conditions with high unmet needs [362]. - The company has exclusive worldwide rights to develop and commercialize small molecule BET inhibitors, including pan-BD and BD2-selective inhibitors [363]. Clinical Trials and Development - VYN202, a BD2-selective BET inhibitor, has shown positive data from a Phase 1a trial and a Phase 1b trial was initiated in February 2025, but was placed on clinical hold by the FDA due to safety concerns [364]. - The Phase 1b trial for repibresib gel (VYN201) in nonsegmental vitiligo did not meet its primary endpoint, leading to the trial's termination in July 2025 [365]. - VYNE has entered into multiple agreements with Tay Therapeutics for the development of BET inhibitors, including milestone payments of up to $15.75 million for clinical development [378]. - The VYN202 License Agreement grants VYNE exclusive rights to develop and commercialize certain BET inhibitor compounds, with a focus on regulatory and marketing activities [380]. Financial Performance - Royalty revenues for the years ended December 31, 2025 and 2024 were $0.6 million and $0.5 million, respectively, representing a 13.8% increase [391]. - Total research and development expenses for the years ended December 31, 2025 and 2024 were $19.2 million and $30.9 million, respectively, reflecting a decrease of $11.7 million or 37.8% [393]. - General and administrative expenses for the years ended December 31, 2025 and 2024 were $11.1 million and $13.2 million, respectively, showing a decrease of approximately $2.1 million or 16.0% [394]. - The company incurred a net loss of $26.5 million for the year ended December 31, 2025, compared to a net loss of $39.8 million for the year ended December 31, 2024, indicating a reduction of $13.3 million or 33.5% [391]. - Other income, net for the years ended December 31, 2025 and 2024 was $3.0 million and $3.8 million, respectively, primarily due to decreased interest income [395]. - The company reported a net loss of $26.5 million for 2025, adjusted for non-cash share-based compensation of $2.3 million [409]. Cash and Capital Management - As of December 31, 2025, the company had cash, cash equivalents, and marketable securities of $29.0 million and an accumulated deficit of $757.7 million [398]. - The company expects to continue incurring net operating losses until it generates adequate revenues to reach profitability, with federal and state net operating loss carryforwards of $332.1 million and $94.2 million, respectively [388]. - The company may require substantial additional capital to continue the development of VYN202 and other product candidates if the Merger is not completed [402]. - The company has no outstanding debt as of December 31, 2025 [398]. - Net cash used in operating activities for the year ended December 31, 2025, was $33.1 million, a slight improvement from $34.0 million in 2024 [409][410]. - Net cash provided by investing activities increased to $37.4 million in 2025 from $23.4 million in 2024, driven by proceeds from marketable securities [411][412]. - The company’s funding sources in 2025 included $68.3 million from the sale and maturity of marketable securities [414]. - The company is currently assessing its future funding needs, which may require seeking additional capital sooner than planned [405]. Merger and Strategic Initiatives - A strategic review initiated in August 2025 resulted in a merger agreement with Yarrow Biosciences, expected to close in Q2 2026, making Yarrow's business the primary focus of VYNE [366][367]. - Yarrow raised $100 million through a Series A Preferred Stock Financing at $4.94 per share, which will support the merger [368]. - A special cash dividend of approximately $14.5 million to $16.5 million is expected to be declared prior to the merger closing [373]. - The company entered into a Merger Agreement on December 17, 2025, which is subject to approval by stockholders and other customary closing conditions [397]. Operational Considerations - The company is subject to macroeconomic risks, including inflation and market volatility, which may impact its financial condition and operations [374]. - The company has no operating lease obligations as of December 31, 2025, following a transition to a fully remote model [415]. - The company has no off-balance sheet arrangements as of December 31, 2025 [417]. - The company had a decrease in trade payables and accrued expenses totaling $12.3 million, primarily due to the wind down of clinical trials [409]. - Cash flows from financing activities remained stable, with net cash used of $0.1 million in both 2025 and 2024 [413]. - Research and development expenses are estimated based on known facts and circumstances, with no material adjustments to prior estimates reported [420].

Core Viewpoint - The Ademi Firm is investigating VYNE for potential breaches of fiduciary duty and legal violations related to its transaction with Yarrow Bioscience [1] Transaction Details - In the transaction, pre-Merger VYNE shareholders are expected to own approximately 3% of the combined company, while pre-Merger Yarrow shareholders are expected to own approximately 97% [2] - VYNE insiders are set to receive substantial benefits as part of change of control arrangements [2] Board Conduct Investigation - The transaction agreement imposes significant penalties on VYNE for accepting competing bids, which may limit competing transactions unreasonably [3] - The investigation focuses on whether the VYNE board of directors is fulfilling their fiduciary duties to all shareholders [3]

Core Viewpoint - Monteverde & Associates PC is investigating VYNE Therapeutics Inc. regarding its merger with Yarrow Bioscience, Inc., questioning the fairness of the deal where VYNE shareholders are expected to own 3% of the combined company [1]. Group 1: Company Overview - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has recovered millions for shareholders [1]. - The firm is headquartered in the Empire State Building, New York City, and specializes in class action securities litigation [2]. Group 2: Legal Context - The firm emphasizes that no one is above the law and encourages shareholders with concerns to seek additional information [3]. - Monteverde & Associates PC has a successful track record in trial and appellate courts, including the U.S. Supreme Court [2].

Core Viewpoint - The conference call is focused on the merger between VYNE Therapeutics and Yarrow Bioscience, highlighting the strategic implications and future expectations of the transaction [1][3]. Group 1: Merger Details - The call is organized to discuss the merger of VYNE and Yarrow Bioscience, indicating a significant corporate development for VYNE [1]. - The merger is expected to involve forward-looking statements regarding future plans and prospects for both companies, which may include risks and uncertainties [3]. Group 2: Communication and Information - The conference call is being recorded for replay, emphasizing the importance of the information being shared [1]. - Participants are advised to refer to the SEC filings, which will include a registration statement containing a proxy statement and a prospectus with important transaction details [4].

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the merger between VYNE Therapeutics Inc. and Yarrow Bioscience, Inc. for VYNE shareholders, who are expected to own approximately 3% of the combined company after the transaction [1]. Group 1 - The investigation focuses on whether VYNE and its board violated federal securities laws or breached fiduciary duties by not obtaining the best possible consideration for shareholders and failing to disclose all material information necessary for assessing the merger [3]. - Halper Sadeh LLC may seek increased consideration for VYNE shareholders, additional disclosures, and other relief related to the proposed transaction [4].

Summary of VYNE Therapeutics and Yarrow Bioscience Conference Call Company and Industry Overview - **Companies Involved**: VYNE Therapeutics and Yarrow Bioscience - **Industry**: Biotechnology, specifically focusing on thyroid autoimmune diseases Key Points and Arguments 1. **Merger Announcement**: VYNE and Yarrow Bioscience have entered into a merger agreement in an all-stock transaction, with Yarrow focused on developing a TSHR antibody for Graves' disease and thyroid eye disease (TED) [4][8] 2. **Leadership Transition**: Dr. Rebecca Frye, CEO of Yarrow, is expected to become the CEO of the combined company post-merger [4][8] 3. **Strategic Review**: VYNE conducted a comprehensive strategic review to maximize stockholder value, leading to the decision to merge with Yarrow [5][9] 4. **Financial Position**: The combined company is projected to have a cash position sufficient to support operations into 2028, bolstered by $200 million from pre-closing private placements [6][8] 5. **Ownership Structure**: Post-merger, pre-merger VYNE stockholders will own approximately 3% of the combined entity, while Yarrow stockholders will own about 97% [6][8] 6. **Cash Dividend**: VYNE plans to pay a cash dividend of approximately $14.5-$16.5 million to pre-merger stockholders before the merger closes [7][8] Yarrow's Pipeline and Strategy 1. **Lead Asset**: Yarrow's lead asset, YB101, is a humanized monoclonal antibody targeting TSHR, currently in a phase one clinical trial for TED in China, with data expected in the first half of 2026 [11][12] 2. **Clinical Trials**: Yarrow plans to initiate a combined phase 1B/2B trial of YB101 for Graves' disease in the U.S. and other territories in the first half of 2026 [12] 3. **Market Need**: Graves' disease affects about 1% of the U.S. population, with 30%-50% of these patients developing TED, indicating a significant unmet medical need [12] 4. **Current Treatment Limitations**: Existing treatments for Graves' disease, such as antithyroid drugs, have limitations and associated toxicities, leading to inadequate disease control in many patients [12][13] 5. **Potential Advantages of YB101**: YB101 aims to provide a convenient subcutaneous administration with a favorable risk-benefit profile, potentially becoming the preferred treatment for patients inadequately controlled by first-line therapies [13][15][16] Market Opportunity 1. **Addressable Market**: The combined market for Graves' disease and TED represents a substantial global commercial opportunity, with YB101 positioned as a potentially breakthrough therapy [16] 2. **Investor Support**: The merger is supported by a syndicate of leading healthcare investors, enhancing the financial backing for Yarrow's clinical programs [6][16] Conclusion - The merger between VYNE and Yarrow is positioned as a strategic move to enhance stockholder value and advance innovative therapies for thyroid autoimmune diseases, with a strong focus on YB101 as a key asset in addressing significant unmet medical needs in the market [5][16]

Merger Announcement - VYNE Therapeutics Inc. and Yarrow Bioscience, Inc. have entered into a definitive merger agreement to combine in an all-stock transaction, with the new entity expected to operate as Yarrow Bioscience, Inc. and trade under the ticker symbol "YARW" on Nasdaq [1][10] Financial Support - A syndicate of healthcare investors led by RTW Investments has committed approximately $200 million in pre-closing financings to support Yarrow [2][7] Cash Position and Funding - The combined company's cash balance at closing is projected to fund operations into 2028, including advancing YB-101 into a Phase 1b/2b trial for Graves' disease (GD) [3][7] Clinical Development - YB-101, a clinical-stage TSHR antibody, is designed to treat GD and thyroid eye disease (TED) and is expected to enter a Phase 1b/2b trial in the U.S. in the first half of 2026, with Phase 1 data anticipated in the second half of 2027 [3][7][9] Dividend Declaration - Prior to closing, VYNE plans to declare a cash dividend to pre-Merger stockholders, estimated to be between $14.5 million and $16.5 million [4] Leadership and Management - The combined company will be led by Rebecca Frey as CEO, with Lori Payton joining as Chief Development Officer [11] Ownership Structure - Post-merger, pre-Merger VYNE stockholders are expected to own approximately 3% of the combined company, while pre-Merger Yarrow stockholders will own about 97% [9] Regulatory Approval - The merger has received unanimous approval from both companies' boards and is expected to close in the second quarter of 2026, pending stockholder approval and other customary closing conditions [10]

Financial Performance - As of September 30, 2025, the company had an accumulated deficit of $752.8 million and recorded net losses of $21.6 million for the nine months ended September 30, 2025, compared to $27.8 million for the same period in 2024[144]. - The net loss for the three months ended September 30, 2025, was $7.3 million, a decrease of 40.1% from a net loss of $12.2 million in the same period of 2024[164][164]. - The net loss for the nine months ended September 30, 2025, was $21.6 million, a decrease of 22.2% from a net loss of $27.8 million in the same period of 2024[170][170]. - Total revenues for the nine months ended September 30, 2025, were $0.4 million, a slight increase of 5.5% from $0.4 million in the same period of 2024[171][170]. - Other income, net for the three months ended September 30, 2025, was $0.4 million, a decrease of 60.8% compared to $0.9 million for the same period in 2024[168][164]. - Other income, net for the nine months ended September 30, 2025, was $2.8 million, a decrease of 10.4% compared to $3.1 million for the same period in 2024[174][170]. - For the nine months ended September 30, 2025, the company incurred a net loss of $21.6 million and used $29.4 million in cash for operations, compared to a net loss of $27.8 million and $25.0 million used in cash for operations in the same period of 2024[177][186][187]. Research and Development - The company has initiated a Phase 1b trial for VYN202 in adult subjects with moderate-to-severe plaque psoriasis, following positive data from a Phase 1a trial[137]. - The FDA placed a clinical hold on the Phase 1b trial due to observed testicular toxicity in dogs, but lifted the hold for female subjects in June 2025[138]. - In a preliminary analysis of the Phase 1b trial, all subjects treated with VYN202 showed improvement in disease symptoms, while the placebo group did not[139]. - The company announced that the Phase 2b trial for repibresib gel in nonsegmental vitiligo did not meet its primary endpoint, but showed a statistically significant treatment effect in a key secondary endpoint[142]. - The company is currently seeking an external partner to continue the development of repibresib gel, which is covered by patents providing exclusivity until at least 2042 in the U.S.[142]. - The company is determining the best path forward for the VYN202 program, which has shown potential in preclinical studies for various serious immune-mediated diseases[141]. Cost Management and Cash Flow - The company has implemented cost reductions expected to extend its cash runway into the first half of 2027[143]. - Research and development expenses for the three months ended September 30, 2025, were $5.3 million, a decrease of 48.7% compared to $10.2 million for the same period in 2024[158][166]. - General and administrative expenses for the three months ended September 30, 2025, were $2.7 million, down 8.7% from $3.0 million in the same period of 2024[159][167]. - Research and development expenses for the nine months ended September 30, 2025, were $16.3 million, representing a decrease of 23.5% from $21.3 million in the same period of 2024[172][170]. - General and administrative expenses for the nine months ended September 30, 2025, were $8.7 million, a decrease of approximately 13.1% from $10.0 million in the same period of 2024[173][170]. - Cash flows from operating activities for the nine months ended September 30, 2025, were primarily affected by a net loss adjusted for non-cash stock-based compensation of $1.8 million[186]. Capital Needs and Financing - The company does not expect to generate product revenue until regulatory approval and commercialization of its product candidates, necessitating substantial additional capital for ongoing operations[179]. - The company had no outstanding debt as of September 30, 2025, and anticipates needing additional capital through equity or debt financings, collaborations, or licensing arrangements[177][179]. - The amount of funds that can be raised through public offerings is limited to one-third of the aggregate market value of shares held by non-affiliates, restricting capital raising efforts until the public float exceeds $75.0 million[181]. - The company may need to seek additional capital sooner than planned due to changes in its operating plan, which could result in dilution to stockholders[183]. - The company has no ongoing material financial commitments that may affect liquidity over the next five years, aside from obligations under the Tay License Agreements[178]. Strategic Initiatives - A strategic review was initiated in August 2025 to evaluate options for maximizing stockholder value, including potential partnerships, licensing, or acquisition opportunities[143]. - The company has incurred net losses since inception, with business activities primarily focused on product development and raising capital[144].

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Financial Position - As of September 30, 2025, VYNE had cash, cash equivalents, and marketable securities totaling $32.7 million, sufficient to fund operations into the first half of 2027[10] - The total stockholders' equity as of September 30, 2025, was $32.1 million, down from $52.1 million at the end of 2024[21] Revenue Performance - Revenues for the third quarter of 2025 were $0.2 million, compared to $0.1 million for the same period in 2024, primarily from royalty revenue[11] - Total revenues for the three months ended September 30, 2025, were $169 million, an increase from $121 million in the same period of 2024, representing a growth of 39.7%[23] - Royalty revenues for the nine months ended September 30, 2025, reached $440 million, compared to $417 million in 2024, indicating a year-over-year increase of 5.5%[23] Expenses and Losses - Research and development expenses decreased by $5.0 million, or 48.7%, to $5.3 million for the third quarter of 2025, down from $10.2 million in the same quarter of 2024[12] - VYNE's general and administrative expenses for the third quarter of 2025 were $2.7 million, a decrease of approximately $0.3 million, or 8.7%, compared to $3.0 million in the same quarter of 2024[14] - Total operating expenses for the three months ended September 30, 2025, were $7,961 million, down from $13,212 million in the same period of 2024, reflecting a decrease of 39.5%[23] - The operating loss for the three months ended September 30, 2025, was $(7,792) million, an improvement from $(13,091) million in the same period of 2024[23] - Net loss for the three months ended September 30, 2025, was $(7,280) million, compared to $(12,157) million in the same period of 2024, showing a reduction of 40.5%[23] - Loss per share from continuing operations for the three months ended September 30, 2025, was $(0.17), an improvement from $(0.29) in the same period of 2024[23] - Research and development expenses for the nine months ended September 30, 2025, totaled $16,260 million, down from $21,262 million in 2024, a decrease of 23.5%[23] - General and administrative expenses for the nine months ended September 30, 2025, were $8,710 million, compared to $10,022 million in 2024, reflecting a decrease of 13.1%[23] - Other income for the three months ended September 30, 2025, was $366 million, compared to $934 million in the same period of 2024[23] Clinical and Strategic Developments - VYNE is conducting a 12-week non-clinical toxicology study of VYN202 in dogs to address a partial hold on clinical trials for male subjects[3] - The strategic review initiated by VYNE's Board of Directors includes evaluating internal pipeline opportunities and potential strategic partnerships or acquisitions[4] - The Phase 1b trial of VYN202 in moderate-to-severe plaque psoriasis was placed on clinical hold by the FDA due to testicular toxicity observations, but the hold was lifted for female subjects[8] - VYNE is seeking a development and commercialization partner for the repibresib gel program, which is covered by patents providing exclusivity into at least 2042 in the U.S.[13] Share Information - Weighted average shares outstanding for the three months ended September 30, 2025, were 42,801 million, slightly up from 42,587 million in the same period of 2024[23]